INSMED Inc
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases. Its current business centers on marketed products ARIKAYCE and BRINSUPRI, while it also advances clinical and pre-clinical programs in respiratory, inflammation & immunology, and neuro/rare disease areas.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved products sold today, led by ARIKAYCE and BRINSUPRI.
Programs such as TPIP and INS1148 aimed at pulmonary and inflammatory airway diseases.
Brensocatib development work targeting hidradenitis suppurativa and related inflammatory disease.
INS1201 and INS1202 programs for DMD and ALS, respectively.
Products
Reported · share of revenue- ARIKAYCE71.5 %
- BRINSUPRI28.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
INSMED sells primarily to healthcare providers and the specialty pharmacy / distributor channels that support prescription access for its approved medicines. Demand is driven by physicians treating rare or severe respiratory diseases, with payor coverage and market access critical to adoption. The company also depends on a small number of large customers and distributor relationships, which makes concentration a meaningful commercial risk.
Pulmonologists and related specialists prescribe ARIKAYCE for refractory MAC lung disease and will be key for future respiratory launches.
Channel partners purchase, stock, and dispense product, making them central to revenue realization and patient access.
Commercial insurers and public programs affect formulary access, rebates, and patient affordability for ARIKAYCE and BRINSUPRI.
Sites enrolling patients in TPIP, INS1148, INS1201, and INS1202 studies support pipeline advancement.
Strategy
INSMED is focused on growing revenue from its approved products while advancing a broader pipeline in respiratory, inflammatory, and rare disease therapeutics. Near term, the company is prioritizing commercial execution for ARIKAYCE and BRINSUPRI, continued clinical development of TPIP and brensocatib, and progression of gene therapy assets INS1201 and INS1202. It also continues to evaluate partnerships, in-licensing, acquisitions, and manufacturing capabilities to support future launches.
ARIKAYCE and BRINSUPRI are the only current revenue engines and fund the pipeline.
New approvals are needed to diversify revenue and reduce dependence on current products.
INS1201 and INS1202 could create new therapeutic franchises if clinical data are positive.
Geography
Q1/2026INSMED commercializes ARIKAYCE in the U.S., Europe, and Japan, and BRINSUPRI in the U.S. The company also seeks patent protection and future market expansion in selected foreign markets, including Europe, Japan, Canada, Australia, China, India, Israel, and Mexico. Geography matters because regulatory approval, reimbursement, and local commercialization capability determine where each product can generate revenue.
Share of the revenue the company reports by geography.
Risks
INSMED is highly dependent on the commercial success and regulatory status of ARIKAYCE and BRINSUPRI, so any setback in approval, reimbursement, or physician adoption could materially affect revenue. The company also faces typical biotech risks: clinical trial failure, manufacturing dependence on third parties, patent protection challenges, and competition from better or cheaper therapies. Customer concentration is another company-specific risk because a small number of customers account for most product revenue.
- Dependence on approved productsImpact: HighLikelihood: Medium
ARIKAYCE and BRINSUPRI are the main commercial assets and drive current sales.
Exposure: Commercial revenue concentration
- Regulatory and clinical development failureImpact: HighLikelihood: Medium
Pipeline value depends on successful trials and approvals for TPIP, brensocatib, and gene therapies.
Exposure: Pipeline programs
- Customer concentrationImpact: HighLikelihood: Medium
The three largest customers represented a very large share of gross product revenue.
Exposure: Distributor and channel relationships
- Manufacturing and supply dependenceImpact: MediumLikelihood: Medium
Commercial supply relies on CMOs such as Patheon and API suppliers such as Esteve.
Exposure: ARIKAYCE and BRINSUPRI supply chain
- Competitive pressureImpact: MediumLikelihood: Medium
Respiratory and rare disease markets include larger pharma and biotech competitors with more resources.
Exposure
Accounting
Judgemental itemsProduct revenue is recorded net of rebates, discounts, service fees, and chargebacks.
Impact: Affects reported ARIKAYCE and BRINSUPRI revenue
Changes in share price can materially change the liability valuation.
Impact: Can drive large non-cash gains or losses in earnings
Acquired assets must be tested for recoverability and may be written down if assumptions weaken.
Impact: Potential non-cash charges to operating results
Commercial launch timing, customer ordering patterns, and clinical spending can shift results between quarters.
Impact: Makes period-to-period comparison less stable
Similar listed companies
Publicly listed companies with a comparable business focus.
InMed Pharmaceuticals Inc.
INM · Pharmaceutical Preparations
Jasper Therapeutics, Inc.
JSPR · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
InflaRx N.V.
IFRX · Pharmaceutical Preparations
Invivyd, Inc.
IVVD · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026